Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes

Circulation

Volumn 101, Issue 4, 2000, Pages 366-371

  Mark, Daniel B ^a   Harrington, Robert A ^a   Lincoff, A Michael ^b   Califf, Robert M ^a   Nelson, Charlotte L ^a   Tsiatis, Anastasios A ^a,c   Buell, Hope ^a   Mahaffey, Kenneth W ^a   Davidson Ray, Linda ^a   Topol, Eric J ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Coronary disease; Cost benefit analysis; Eptifibatide; Glycoproteins

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; ST SEGMENT ELEVATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0034142190     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.4.366     Document Type: Article

References (7)

1. The PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation. N Engl J Med. 1998;339:436-443.
2. Mark DB. Medical economics in cardiovascular medicine. In: Topol EJ, ed. Textbook of Cardiovascular Medicine. New York, NY: Lippincott-Raven; 1997:1033-1062.
3. 1998 Drug Topics Red Book. Montvale, NJ: Medical Economics Data; 1998.
4. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
5. Mauri F, Maggioni AP, Franzosi MG, Santoro L. Prognostic significance of myocardial infarction extent over 10 years of follow-up in the GISSI-1 patients. J Am Coll Cardiol. 1999;33:379A. Abstract.
6. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL, Clapp-Channing NE, Knight JD, Harrell FE Jr, Simes J, Topol EJ. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332: 1418-1424.
7. Kong DF, Califf RM, Miller DP, Moliterno D, White HD, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829-2835.